The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit ...

During a live event, Gary J. Schiller, MD, reviewed the diagnostics and characteristics of blastic plasmacytoid dendritic ...

A blastic plasmacytoid dendritic-cell neoplasm is a rare tumor with very aggressive clinical behavior and no established treatment. 1 Available treatment options include aggressive multiagent ...

Patients with blastic plasmacytoid dendritic cell neoplasms can enroll in the ongoing CADENZA trial, which is investigating the safety and efficacy of the novel agent pivekimab sunirine in patients ...

In these conditions, mature plasmacytoid dendritic cells lack CD56, and their presence is not indicative ... between pathologists and clinicians at Butaro District Hospital/Cancer Centre of Excellence ...

A new research perspective was published in Genes & Cancer on January 30, 2023, entitled, "Leveraging a powerful allogeneic dendritic ... on an allogeneic Plasmacytoid DC cell line, which is ...

A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN).

Dendritic cells (DC ... and express myeloid-specific markers. Plasmacytoid DCs resemble plasma cells and do not express myeloid markers. Their primary role is thought to be in response to viral ...

BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines ...